Characterization of a COPD-Associated *NPNT* Functional Splicing Genetic Variant in Human Lung Tissue via Long-Read Sequencing

Aabida Saferali[1], Zhonghui Xu[1], Gloria M. Sheynkman[2,3,4], Craig P. Hersh[1,5], Michael H. Cho[1,5], Edwin K. Silverman[1,5], Alain Laederach[6], Christopher Vollmers[7], Peter J. Castaldi[1,8]

[1]Channing Division of Network Medicine, Brigham and Women's Hospital
[2]Department of Molecular Physiology and Biological Physics, University of Virginia
[3]Center for Public Health Genomics, University of Virginia
[4]UVA Cancer Center, University of Virginia
[5]Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital
[6]Department of Biology, University of North Carolina at Chapel Hill
[7]Department of Biomolecular Engineering, Cellular, Cellular, and Developmental Biology, University of California Santa Cruz
[8]Division of General Medicine and Primary Care, Brigham and Women's Hospital

Abstract:

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. Genome-wide association studies (GWAS) have identified over 80 loci that are associated with COPD and emphysema, however for most of these loci the causal variant and gene are unknown. Here, we utilize lung splice quantitative trait loci (sQTL) data from the Genotype-Tissue Expression project (GTEx) and short read sequencing data from the Lung Tissue Research Consortium (LTRC) to characterize a locus in nephronectin (*NPNT*) associated with COPD case-control status and lung function. We found that the rs34712979 variant is associated with alternative splice junction use in *NPNT*, specifically for the junction connecting the 2nd and 4th exons (chr4:105898001-105927336) (p=4.02×10^{-38}). This association colocalized with GWAS data for COPD and lung spirometry measures with a posterior probability of 94%, indicating that the same causal genetic variants in *NPNT* underlie the associations with COPD risk, spirometric measures of lung function, and splicing. Investigation of *NPNT* short read sequencing revealed that rs34712979 creates a cryptic splice acceptor site which results in the inclusion of a 3 nucleotide exon extension, coding for a serine residue near the N-terminus of the protein. Using Oxford Nanopore Technologies (ONT) long read sequencing we identified 13 *NPNT* isoforms, 6 of which are predicted to be protein coding. Two of these are full length isoforms which differ only in the 3 nucleotide exon extension whose occurrence differs by genotype. Overall, our data indicate that rs34712979 modulates COPD risk and lung function by creating a novel splice

acceptor which results in the inclusion of a 3 nucelotide sequence coding for a serine in the nephronectin protein sequence. Our findings implicate *NPNT* splicing in contributing to COPD risk, and identify a novel serine insertion in the nephronectin protein that warrants further study.

Introduction

The development of chronic obstructive pulmonary disease (COPD) is influenced by

genetic susceptibility factors in addition to environmental exposures. Recent genome-wide

association studies (GWAS) have identified over 80 distinct genetic loci that influence

susceptibility to COPD and emphysema[1], but for most of these loci the causal genetic variants

and effector genes are unknown. By identifying the functional genetic variants in these GWAS

loci and elucidating the biological mechanisms through which they influence disease

susceptibility, causal mechanisms of COPD may be discovered.

The large majority of causal GWAS variants reside in the non-coding genome and disrupt

gene regulatory elements. As a result, expression quantitative trait locus (eQTL) studies that

associate genetic variants to gene expression values have been used to identify functional gene

targets of GWAS-identified loci. In COPD, this approach has identified putative causal variants

affecting the expression of *HHIP*[2], *FAM13A*[3], *TGFB2*[4], and *ACVR1B*[5]. However, eQTL studies

do not capture all of the potentially relevant functional mechanisms through which causal

variants may alter gene expression. In particular, the alteration of gene splicing and isoform

ratios is an important disease-causing gene regulatory mechanism that is not well captured by

gene-level eQTL analyses[6,7].

A genome-wide significant and replicated genetic association signal for respiratory

phenotypes near *NPNT* may harbor a causal splicing variant, because the pattern of association at

this locus is characterized by a single, clear lead SNP association that is located 5 nucleotides

upstream from the 5' splice site of the second exon in *NPNT*. We hypothesized that this region

contains a functional variant that alters *NPNT* splicing. We utilized short and long-read RNA

sequencing from human lung tissues to identify a causal splicing variant, rs34712979; to catalog

the isoform variability of *NPNT* in the human lung; and to characterize the effects of rs34712979

on isoform usage rates.

Methods

Genetic association analysis, splicing QTL, and colocalization results

Summary genome-wide association study (GWAS) statistics were used from our previous

study of COPD[1] and two lung function phenotypes, FEV_1 and FEV_1/FVC

(http://ldsc.broadinstitute.org/ldhub/)[8]. Leafcutter splicing QTL (sQTL) significant results[9] were

obtained for all tissues from the GTEx Portal (https://www.gtexportal.org/home/datasets), and

complete lung sQTL results were obtained from the Anvil GTEx Terra workspace. Multiple

colocalization for GWAS and sQTL results was performed using the moloc R package

(https://github.com/clagiamba/moloc). Moloc analyses were performed using default parameters

for prior variance of the approximate Bayes factor (ABF, prior_var = c(0.01, 0.1, 0.5)) and

default parameters for the prior likelihood that a given SNP is causal for one trait, pairs of traits,

or all traits (priors = c(1e-04, 1e-06, 1e-07). Linkage disequilibrium (LD), evolutionary

conservation, and overlap with regulatory elements were identified for individual single

nucleotide polymorphisms (SNPs) with Haploreg

(https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php). Posterior causal probabilities

based on strength of genetic association and local LD patterns were determined using the PICS

algorithm (https://pubs.broadinstitute.org/pubs/finemapping/pics.php).[10]

Splicing analysis in short read RNA-seq data from GTEx lung tissue samples

With dbGaP approval, RNA-seq BAM files and whole genome sequencing VCF files for

lung tissue samples in GTEx V8 release were accessed on Google Cloud via the AnVIL GTEx

Terra workspace (https://app.terra.bio/#workspaces/anvil-datastorage/AnVIL_GTEx_V8_hg38).

To obtain splicing junctional counts for each genotype and visualize with Sashimi plots, a

Docker image (https://hub.docker.com/repository/docker/pacifly/splice-plot-app) was built on

the Python package SplicePlot[11] (https://github.com/wueric/SplicePlot) and its dependencies, and

a WDL workflow

(https://portal.firecloud.org/?return=terra#methods/zxu_spliceplot/spliceplot/18) was created and

executed via Cromwell engine to run SplicePlot functionalities on Google Cloud. The splicing

junctional count method in SplicePlot was adapted to accommodate novel junctions missed from

the alignment.

Lung Tissue Research Consortium Samples, short-read RNA sequencing, and whole genome

sequencing

The Lung Tissue Research Consortium (LTRC) is an NHLBI-sponsored collection of

lung and blood tissues collected from patients undergoing thoracic surgery who completed a

standard questionnaire, pulmonary function testing, and chest computed tomography (CT)

imaging. Through the NHLBI Trans-Omics and Precision Medicine (TOPMed) program, LTRC

whole-genome sequencing (WGS) data were generated at Broad Genomics and lung RNA-seq

were generated at the University of Washington, and 1,335 LTRC samples with RNA-seq and

WGS passing quality control filters were analyzed in this study. Briefly, RNA-seq data were

generated using paired-end Illumina sequencing from poly-A selected libraries to an average

depth of 67 million mapped reads. Methods for TOPMed WGS are available at

https://www.nhlbiwgs.org/topmed-whole-genome-sequencing-methods-freeze-8.

Long read RNA-seq analysis in human lung samples from the LTRC

72   We conducted targeted Oxford Nanopore Technologies (ONT) long read sequencing on

73   RNA from 10 human lung samples from the LTRC which were selected to include five samples

74   from each homozygous class (i.e., GG genotype, AA genotype) of rs34712979. For each of these

75   ten samples, 100-200ng of total RNA was used to generate full-length cDNA using a modified

76   Smart-seq2 protocol[12]. The enrichment and library generation procedures are described in detail

77   in the Supplemental Methods.

78   Enriched re-amplified cDNA from two independent enrichment reactions was sequenced

on a MinION 9.4.1 flow cell or a MinION 10.3 flow cell using the R2C2 method[13-16]. For each

run, 1ug of DNA was prepared using the LSK-109 kit according to the manufacturer's

instructions with only minor modifications. End-repair and A-tailing steps were both extended

from 5 minutes to 30 minutes. The final ligation step was also extended to 30 minutes. Each run

took 48 hours and the resulting data in Fast5 format was basecalled using the high accuracy

model of the gpu accelerated Guppy algorithm (9.4.1 flow cell: version 3.4.5+fb1fbfb with

config file dna_r9.4.1_450bps_hac.cfg config file; 10.3 flow cell: version 3.6.1+249406c with

config file dna_r10_450bps_hac.cfg). To generate R2C2 consensus reads for each sample, we

processed and demultiplexed the resulting raw reads using our C3POa pipeline

(https://github.com/rvolden/C3POa). R2C2 reads were analyzed to identify and quantify

isoforms using version 3.5 of Mandalorion (-O 0,40,0,40 -r 0.01 -i 1 -w 1 -n 2 -R 5)

(https://github.com/rvolden/Mandalorion-Episode-III). Isoforms were categorized using the

sqanti_qc.py script of the SQANTI[17] program with slight modifications to make it compatible

with Python3.

For *NPNT* isoform quantification (i.e., usage analysis), the proportion of isoform usage

for each sample was calculated by dividing the number of reads for each isoform by the total

number of isoform reads aligning to the *NPNT* locus. Differences in isoform usage between

genotype classes were identified using the Mann-Whitney test. For certain analyses, isoform

reads were collapsed based on whether they contained a 3 nucleotide exon extension. To

quantify the number of reads containing this TAG sequence at the 5' end of the second exon, we

extracted the following 30-mers from the fasta files for each sample using the 'grep' command:

101   AGTTCGACGGGAG<u>TAG</u>GTGGCCCAGGCAAA

102   CGAGTTCGACGGGAGGTGGCCCAGGCAAAT

NPNT protein sequence analysis

Protein sequence analysis was performed using Uniprot[18] to identify NPNT protein domains. The

Chou and Fasman Secondary Structure Prediction server[19] was used to characterize the impact of

sequence changes to NPNT structure.

Results

Genetic association signals for respiratory phenotypes in NPNT

Genome-wide significant association signals near *NPNT* have been identified for COPD

and various measures of lung function, and previous colocalization and fine mapping analyses

have implicated rs34712979 as the most likely causal variant for the COPD association near

NPNT[1]. We obtained the summary GWAS statistics for the most recent GWAS meta-analyses of

COPD, FEV_1, and FEV_1/FVC and compared the genetic association signal for each of these

phenotypes. In each case, the variant with minimal p-value was rs34712979, a common variant

with a minor allele frequency of 23% in the 1,000 Genomes European (EUR) population. Using

the PICS algorithm, we determined that the estimated posterior probability that rs34712979 was

the causal variant for each of these associations was between 94-100%. This variant is in strong

linkage disequilibrium with only one other common variant, rs6828309 ($r^2 = 0.81$ in EUR).

Supplemental Table 1 shows that rs34712979 is highly conserved and overlaps promoter and

enhancer elements in multiple cell types, which is not the case for rs6828309 (Supplemental

Table 1). The minor A allele of rs34712979 is associated with lower measures of lung function
and increased risk of COPD (odds ratio=1.48).

An NPNT splicing association signal in human lung tissue colocalizes with GWAS associations

127   To determine whether the genetic associations near *NPNT* to pulmonary phenotypes may
be explained by genetic effects on splicing, we examined leafcutter quantitative trait locus (QTL)
results from 49 tissues obtained from a total of 838 subjects in GTEx version 8. We observed
that rs34712979 was associated with splicing ratios for three exon-exon junctions in a total of 18
tissues that connect the first and second, second and fourth, and third and fourth exons of *NPNT*
(GENCODE v32) (Supplemental Table 2). Focusing on lung tissue, the most relevant tissue for
COPD, we observed that rs34712979 was associated with multiple splicing ratios at a nominal p-
value threshold of p<0.001 (Supplemental Table 3), with the association for the junction
connecting the 2nd and 4th exons (chr4:105898001-105927336) exceeding genome-wide
significance. To better understand the effect of rs34712979 on splicing in human lung, we
identified 27 subjects in GTEx homozygous for the A allele of rs34712979 and compared the
distribution of junctional reads from lung RNA in these subjects against 27 randomly selected
samples from the other two genotype classes (Figure 1), and found that the A allele results in
higher rates of inclusion of the 3rd exon. Upon further investigation of junctional reads flanking
exon 2 we discovered the presence of a novel splice site acceptor at the 5' end of exon 2
associated with the A allele. This novel cryptic splice site was not detected in the sQTL analysis
as 99.6% of reads using the cryptic splice site were soft-clipped (ie. portions of the read were
masked due to a mismatch with the reference genome) and therefore were not included in the
Leafcutter clustering step.

Figure 1. GTEx Leafcutter lung sQTL results for effect of rs34712979 on splice junctions involving the 2nd-4th exons of *NPNT* in leafcutter splicing analysis from short-read RNAseq in 515 GTEx samples (A) and in junctional reads from 27 samples from each genotype class of rs34712979 (B). The 3 nucleotide alternatively spliced exonic extension sequence is shown in the inset window of panel B.

To confirm that the lung sQTL signals in this region overlap with the GWAS association signals, we performed multiple colocalization using the moloc method which resulted in an estimated 94% probability of a shared causal variant for the three genetic association signals and the lung splicing signal for the 2nd and 4th exons of *NPNT* (chr4:105898001-105927336). rs34712979 had the best individual SNP posterior probability across all evaluated scenarios, with a posterior probability of 94% for the scenario of shared colocalization across all four datasets (Supplemental Table 4). The local association plots for each of the association signals near *NPNT* is shown in Figure 2.

Figure 2. Local association plots for genetic association near *NPNT* to COPD (A,

Sakornsakolpat 2019), FEV1 (B), FEV1/FVC (C, Shrine 2019), and GTEx Leafcutter lung sQTL

analyses (D).

rs34712979 creates an alternative splice acceptor site

rs34712979 is located 5bp upstream of the second exon of *NPNT*, so we examined the

sequence content in this region for motifs that may alter splicing, and we observed that the minor

A allele of rs34712979 creates a cryptic AG splice acceptor that would result in a 3 nucleotide 5'

exon extension in exon 2. In other words, the A allele creates a NAGNAG splice site, which

contains adjacent AG acceptor sites that can be variably used[20,21]. Open reading frame analysis

indicates that this results in an additional in-frame AGT codon, coding for serine, spanning the

boundaries of the first and second exon (Figure 3).

To confirm this effect in human lung samples, we queried short-read RNA-seq data from

human lung samples in GTEx and confirmed that samples with the A allele demonstrate

preferential use of the cryptic versus the annotated splice acceptor site (Figure 4). We further

confirmed that this phenomenon occurs in a larger set of 1,335 lung samples from the LTRC

(Figure 4).

Figure 3. The A allele of rs34712979 creates an alternative splice acceptor site resulting in

inclusion of a serine at the 5' splice site of exon 2.

Figure 4. Violin plot of exon 2 alternative splice site usage in short-read RNA-seq from A)

LTRC and B) GTEX Lung Tissue Samples.

Characterization of rs34712979 Allelic Effects on NPNT Isoform Usage

To determine the effect of rs34712979 on full-length NPNT isoforms, we performed

targeted enrichment for *NPNT* transcripts followed by ONT long-read sequencing in lung tissue

samples from the LTRC selected to include 5 subjects from each homozygote class of

rs34712979. The experiment yielded 24,747 reads mapping to *NPNT*. Thirteen high confidence

isoforms were detected, 12 of which were novel (Supplemental Table 1). Six of these isoforms,

including one antisense isoform, have open reading frames indicating that they have protein-

coding potential. Two protein coding isoforms containing exon 2 utilize the cryptic splice

acceptor, while two isoforms utilize the annotated splice acceptor (Figure 5, panel A).

Isoform usage differed between rs34712979 genotype classes. On a per-isoform basis, 9

of the 13 isoforms show differential usage between the two homozygous genotype classes

(Mann-Whitney p<0.05). Focusing on the putative protein-coding isoforms, we found that the

full length annotated isoform 'coding_5' (corresponding to ENST00000379987.6) is more highly

expressed in the GG genotype class, while isoform 'coding_1', also full length, is highly

expressed in 4 out of 5 subjects with the AA genotype (Figure 6). The three short isoforms are

also differentially expressed by genotype, with isoforms 'coding 3' and 'coding 4' more highly

expressed in AA. Looking specifically at usage of the alternative or canonical splice acceptor

site at the 5' end of exon 2, we observed 10 isoforms that include the second exon, with five

isoforms each using the alternative or canonical splice acceptor. Collapsing these isoforms by

splice site usage demonstrates markedly increased usage of the alternative splice site in the AA

genotype, with essentially no usage of the alternative site in 4 of the 5 GG genotype class

samples (Figure 6, panel E). We confirmed the presence of the 3-nucleotide 5' exon extension

sequence in full length reads by counting the reads containing a 30-bp sequence centered on the

TAG triplet located after the novel splice junction and compared this to the number of reads

containing a corresponding 30-bp sequence without the TAG. Table 1 shows the clear

association between the AA genotype and the 3-nucleotide exon extension event.

Figure 5. Isoforms detected by long read sequencing in 10 human lung tissues predicted to be coding or noncoding (A) * Indicates isoforms utilizing the novel splice acceptor site resulting in a three nucleotide 5' extension of exon 2. The isoform usage profile differs markedly between rs34712979 GG (B) and AA homozygotes (C).

Figure 6. Long read sequencing confirms the presence of two full length isoforms, one

incorporating a 3 bp intronic sequence (A) and the other which is fully annotated (B). Out of the

two short isoforms (coding isoforms 2 and 3) which contain exon 2, one includes the upstream

cryptic splice site and is more highly expressed in samples homozygous for the rs34712979 AA

genotype (C), while the other is predominantly expressed in the GG genotype (D). All isoforms

using the cryptic splice site combined have increased expression in the AA genotype with

minimal expression in GG.

Protein sequence analysis

The serine residue 5' exon extension is inserted 24 residues from the N-terminus of NPNT

protein, and four amino-acids after the end of the predicted signal peptide. Protein secondary

structure analysis of NPNT isoform sequences with and without the 3 nucleotide exon extension

revealed that the serine residue results in the perturbation of an alpha-helical segment with a turn

motif (Supplemental Figure 1).

Discussion

Our results provide strong support for the hypothesis that rs34712979 is a functional

GWAS variant that acts by altering isoform usage of *NPNT*. Our analyses led to three main

findings: 1) the genetic association patterns of association to COPD, FEV1 and FEV1/FVC near
NPNT are highly likely to share rs34712979 as a causal genetic variant, 2) the A allele of
rs34712979 creates an alternative splice acceptor site that results in a 3-nucleotide exon
extension at the 5' end of exon 2 that is predicted to result in the addition of a serine to the
NPNT protein, and 3) the A allele alters *NPNT* isoform usage. The genetic association patterns
reflect the cumulative data of hundreds of thousands of subjects, and the splicing effects were
demonstrated in lung RNA from over 1,000 subjects in two different human cohorts.
NPNT, or nephronectin, is an extracellular protein involved in tissue development,
remodeling, and repair. It was first identified in the context of the search for a novel ligand for
integrin α8β1[22,23]and was shown to be necessary for normal kidney development in murine
models[24]. NPNT has also been linked to osteoblast differentiation and bone remodeling[25],
invasiveness of breast cancer[26], and pulmonary silicosis[27]. Full-length NPNT protein includes
five epidermal growth factor (EGF)-like functional domains followed by a meprin, A-5 protein,
receptor protein-tyrosine phosphatase mu (MAM), and an Arg-Gly-Asp (RGD) integrin-binding
domain. The most well-described function of NPNT is as an extra-cellular matrix protein that
binds integrin α8β1 through its RGD domain. Recently, NPNT has been identified in
extracellular vesicles secreted by a murine breast cancer cell line, and full-length NPNT has been
reported to undergo post-translational modifications including cleavage to a shorter 20-kd
isoform[28]. Full length NPNT has also been shown to be highly expressed in human pneumocytes
in the Human Protein Atlas project[29]. Previous studies have identified NPNT as a potential
effector gene via association between lung function and mRNA levels and NPNT staining in
pulmonary endothelial and alveolar epithelial cells[30]. In our study, we identify two full length
NPNT isoforms, one of which is fully annotated while the other utilizes a cryptic splice acceptor
in exon 2, in addition to three shortened isoforms that are likely protein coding. Within the pair
of long isoforms and within the pair of short isoforms, they differ only in the inclusion of a three
nucleotide 5' exon extension coding for a serine residue near the N-terminus of the protein.
Additional studies are needed to confirm the extent to which these differences at the RNA level
translate to differences in pulmonary protein isoform content, structure and function.
The *NPNT* genetic association lies in a region first described in association with lung
function[31,32]. Subsequent studies confirmed an association with COPD and also identified two
independent signals at this locus[33]. Several genes in this region have previously been

hypothesized to be the effector genes using eQTL studies, including the nearby genes *GSTCD*

and *INTS12*. These two genes harbor eQTL in blood and lung, and prior studies have found

correlations between *GSTCD* and *INTS12* mRNA with lung function and variable expression

during lung development[34]. Additional studies identified *NPNT* as another potential effector gene

at this locus[1,30], indicating that the genetic association at this locus likely involves several

different genes and mechanisms.

From a genetic standpoint, the most clear and compelling genetic associations of *NPNT*

to common disease colocalize to an area including the second exon with clear evidence that

rs34712979 is a causal variant contributing to the association signals to lung function[8,35] and

COPD[1]. Our RNA-seq analyses provide strong evidence that the A allele of rs34712979 (which

is associated with decreased pulmonary function and increased COPD risk) creates an alternative

splice acceptor site at the 5' end of the second exon, and this site is preferentially used relative to

the annotated splice site on haplotypes containing the A allele. Usage of this alternative splice

site results in the inclusion of a serine residue near the N-terminus of the protein that is predicted

to perturb an alpha-helical segment with a turn motif. In addition to this alternative acceptor site

usage, the A allele substantially alters *NPNT* isoform usage patterns. While some of the isoform

changes can be directly explained by the second exon alternative splice site usage event, our

analysis also identified allelic effects on downstream splicing events as well. The mechanisms

that may link usage of alternative splice site to other splicing events remain to be elucidated.

As is characteristic of human GWAS associations, the penetrance of the rs34712979 A

allele is low, indicating that either the overall effect of this allele on biological function is subtle

or that the effect is large but occurs only in restricted sub-populations. Additional research on

NPNT isoform expression at the RNA and protein levels in large, well-phenotyped human

cohorts may identify specific sub-populations most impacted by the functional consequences of

this allele.

The strengths of this study are that the GWAS and RNA-seq findings are based on the

analysis of a very large number of human samples, and the integrated analysis of short and long-

read RNA-seq data provides a high level of resolution to observe changes at the isoform level.

To our knowledge this is one of the first applications of long-read sequencing to human tissue

samples to demonstrate splicing-related effects of a GWAS-identified genetic variant. Important

limitations to consider are that long-read sequencing technologies can be affected by biases

related to transcript length, therefore direct comparisons of abundance between the short and

long isoforms of *NPNT* should be interpreted with caution. The most prominent finding in our

study, namely allele-specific alternative splice site usage, is clearly identified in isoforms of

equal length suggesting that these allele-specific observations are unlikely to be affected by this

bias. While there is strong statistical support for our findings, these are nonetheless correlative

findings from large human cohorts and future work is required to define the underlying

molecular mechanisms and provide further experimental evidence to demonstrate how these

mechanisms may alter COPD risk.

In summary, these analyses demonstrate that the pulmonary disease GWAS association

near NPNT is very likely to be mediated by a common genetic variant that alters splicing,

resulting in the insertion of a novel serine residue in the NPNT protein immediately downstream

of the signal peptide domain. Given the known function of NPNT in extracellular matrix biology

and the high expression of NPNT in lung tissue and pneumocytes[30], further investigation of the

functional consequences of this splicing variant, including its effects on NPNT protein structure

and function, are likely to elucidate causal mechanisms of COPD pathogenesis.

Table 1. Number of ONT reads containing 30bp sequences including and excluding the TAG

sequence at the 5' end of the 2nd exon of NPNT.

rs34712979	...GATTAGGTG...	...GATGTG...
AA	825	206
AA	735	163
AA	291	92
AA	1638	403
AA	2041	500
GG	10	2216
GG	2	1519
GG	8	51
GG	6	502
GG	1	1553

Funding/Acknowledgements: This work was funded by R01 HL124233, R01 HL147326, R01

HL111527, U01 HL089897, U01 HL089856, R01HL125583, R01HL130512, T32HL007427.

Research reported in this publication was supported by the NHLBI and FDA Center for Tobacco

Products (CTP). The content is solely the responsibility of the authors and does not necessarily

represent the official views of the NIH or the Food and Drug Administration.

The Genotype-Tissue Expression (GTEx) Project was supported by the [Common Fund](#) of the

Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,

NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained

from: the GTEx Portal between January and August of 2020 and via the GTEx Terra Workspace

during the same time interval.

Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by

the National Heart, Lung and Blood Institute (NHLBI). Whole Genome Sequencing and

RNASeq for "NHLBI TOPMed: The Lung Tissue Research Consortium (phs001662)" was

performed at Northwest Genome Center (NWGC, HHSN268201600032I, RNASeq) and Broad

Genomics (HHSN268201600034I, WGS)   Core support including centralized genomic read

mapping and genotype calling, along with variant quality metrics and filtering were provided by

the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract

HHSN268201800002I). Core support including phenotype harmonization, data management,

sample-identity QC, and general program coordination were provided by the TOPMed Data

Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We

gratefully acknowledge the studies and participants who provided biological samples and data

for TOPMed.

COPDGene® Investigators – Core Units:

Administrative Center: James D. Crapo, MD (PI); Edwin K. Silverman, MD, PhD (PI); Barry J.
Make, MD; Elizabeth A. Regan, MD, PhD

391
392 *Genetic Analysis Center*: Terri Beaty, PhD; Ferdouse Begum, PhD; Peter J. Castaldi, MD, MSc;
393 Michael Cho, MD; Dawn L. DeMeo, MD, MPH; Adel R. Boueiz, MD; Marilyn G. Foreman,
394 MD, MS; Eitan Halper-Stromberg; Lystra P. Hayden, MD, MMSc; Craig P. Hersh, MD, MPH;
395 Jacqueline Hetmanski, MS, MPH; Brian D. Hobbs, MD; John E. Hokanson, MPH, PhD; Nan
396 Laird, PhD; Christoph Lange, PhD; Sharon M. Lutz, PhD; Merry-Lynn McDonald, PhD;

Margaret M. Parker, PhD; Dmitry Prokopenko, Ph.D; Dandi Qiao, PhD; Elizabeth A. Regan, MD, PhD; Phuwanat Sakornsakolpat, MD; Edwin K. Silverman, MD, PhD; Emily S. Wan, MD; Sungho Won, PhD

Imaging Center: Juan Pablo Centeno; Jean-Paul Charbonnier, PhD; Harvey O. Coxson, PhD; Craig J. Galban, PhD; MeiLan K. Han, MD, MS; Eric A. Hoffman, Stephen Humphries, PhD; Francine L. Jacobson, MD, MPH; Philip F. Judy, PhD; Ella A. Kazerooni, MD; Alex Kluiber; David A. Lynch, MB; Pietro Nardelli, PhD; John D. Newell, Jr., MD; Aleena Notary; Andrea Oh, MD; Elizabeth A. Regan, MD, PhD; James C. Ross, PhD; Raul San Jose Estepar, PhD; Joyce Schroeder, MD; Jered Sieren; Berend C. Stoel, PhD; Juerg Tschirren, PhD; Edwin Van Beek, MD, PhD; Bram van Ginneken, PhD; Eva van Rikxoort, PhD; Gonzalo Vegas Sanchez-Ferrero, PhD; Lucas Veitel; George R. Washko, MD; Carla G. Wilson, MS;

PFT QA Center, Salt Lake City, UT: Robert Jensen, PhD

Data Coordinating Center and Biostatistics, *National Jewish Health, Denver, CO*: Douglas Everett, PhD; Jim Crooks, PhD; Katherine Pratte, PhD; Matt Strand, PhD; Carla G. Wilson, MS

Epidemiology Core, *University of Colorado Anschutz Medical Campus, Aurora, CO*: John E. Hokanson, MPH, PhD; Gregory Kinney, MPH, PhD; Sharon M. Lutz, PhD; Kendra A. Young, PhD

Mortality Adjudication Core: Surya P. Bhatt, MD; Jessica Bon, MD; Alejandro A. Diaz, MD, MPH; MeiLan K. Han, MD, MS; Barry Make, MD; Susan Murray, ScD; Elizabeth Regan, MD; Xavier Soler, MD; Carla G. Wilson, MS

Biomarker Core: Russell P. Bowler, MD, PhD; Katerina Kechris, PhD; Farnoush Banaei-Kashani, Ph.D   **COPDGene® Investigators – Clinical Centers**
Ann Arbor VA: Jeffrey L. Curtis, MD; Perry G. Pernicano, MD

Baylor College of Medicine, Houston, TX: Nicola Hanania, MD, MS; Mustafa Atik, MD; Aladin Boriek, PhD; Kalpatha Guntupalli, MD; Elizabeth Guy, MD; Amit Parulekar, MD;

Brigham and Women's Hospital, Boston, MA: Dawn L. DeMeo, MD, MPH; Alejandro A. Diaz, MD, MPH; Lystra P. Hayden, MD; Brian D. Hobbs, MD; Craig Hersh, MD, MPH; Francine L. Jacobson, MD, MPH; George Washko, MD

Columbia University, New York, NY: R. Graham Barr, MD, DrPH; John Austin, MD; Belinda D'Souza, MD; Byron Thomashow, MD

Duke University Medical Center, Durham, NC: Neil MacIntyre, Jr., MD; H. Page McAdams, MD; Lacey Washington, MD

Grady Memorial Hospital, Atlanta, GA: Eric Flenaugh, MD; Silanth Terpenning, MD

HealthPartners Research Institute, Minneapolis, MN: Charlene McEvoy, MD, MPH; Joseph Tashjian, MD

Johns Hopkins University, Baltimore, MD: Robert Wise, MD; Robert Brown, MD; Nadia N. Hansel, MD, MPH; Karen Horton, MD; Allison Lambert, MD, MHS; Nirupama Putcha, MD, MHS

Lundquist Institute for Biomedical Innovationat Harbor UCLA Medical Center, Torrance, CA: Richard Casaburi, PhD, MD; Alessandra Adami, PhD; Matthew Budoff, MD; Hans Fischer, MD; Janos Porszasz, MD, PhD; Harry Rossiter, PhD; William Stringer, MD

Michael E. DeBakey VAMC, Houston, *TX*: Amir Sharafkhaneh, MD, PhD; Charlie Lan, DO

Minneapolis VA: Christine Wendt, MD; Brian Bell, MD; Ken M. Kunisaki, MD, MS

National Jewish Health, Denver, CO: Russell Bowler, MD, PhD; David A. Lynch, MB

Reliant Medical Group, Worcester, MA: Richard Rosiello, MD; David Pace, MD

Temple University, Philadelphia, PA: Gerard Criner, MD; David Ciccolella, MD; Francis Cordova, MD; Chandra Dass, MD; Gilbert D'Alonzo, DO; Parag Desai, MD; Michael Jacobs, PharmD; Steven Kelsen, MD, PhD; Victor Kim, MD; A. James Mamary, MD; Nathaniel Marchetti, DO; Aditi Satti, MD; Kartik Shenoy, MD; Robert M. Steiner, MD; Alex Swift, MD; Irene Swift, MD; Maria Elena Vega-Sanchez, MD

University of Alabama, Birmingham, AL: Mark Dransfield, MD; William Bailey, MD; Surya P. Bhatt, MD; Anand Iyer, MD; Hrudaya Nath, MD; J. Michael Wells, MD

University of California, San Diego, CA: Douglas Conrad, MD; Xavier Soler, MD, PhD; Andrew Yen, MD

University of Iowa, Iowa City, IA: Alejandro P. Comellas, MD; Karin F. Hoth, PhD; John Newell, Jr., MD; Brad Thompson, MD

University of Michigan, Ann Arbor, MI: MeiLan K. Han, MD MS; Ella Kazerooni, MD MS; Wassim Labaki, MD MS; Craig Galban, PhD; Dharshan Vummidi, MD

University of Minnesota, Minneapolis, MN: Joanne Billings, MD; Abbie Begnaud, MD; Tadashi Allen, MD

University of Pittsburgh, Pittsburgh, PA: Frank Sciurba, MD; Jessica Bon, MD; Divay Chandra, MD, MSc; Carl Fuhrman, MD; Joel Weissfeld, MD, MPH

University of Texas Health, San Antonio, San Antonio, TX: Antonio Anzueto, MD; Sandra Adams, MD; Diego Maselli-Caceres, MD; Mario E. Ruiz, MD; Harjinder Singh

Conflict of Interest Statement: P. Castaldi has received personal fees and grant support from

GlaxoSmithKline and Novartis. C.Hersh has received grants from NHLBI, Bayer, Boehringer-

Ingelheim, Novartis and Vertex. M. Cho has received grant support from GSK and Bayer, and

speaking or consulting fees from AstraZeneca and Illumina. E. Silverman has received grant

support from GSK and Bayer. A. Laederach reports grants from the NIH NHLBI and consultant

fees from Ribometrix. C. Vollmers has filed patent applications on aspects of the R2C2 method.

References

1. Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., Reeve, N.F., Guyatt, A.L., Jackson, V.E., Shrine, N., Qiao, D., Bartz, T.M., Kim, D.K., et al. (2019). Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nature Genetics *51*, 494–505.

2. Zhou, X., Baron, R.M., Hardin, M., Cho, M., Zielinski, J., Hawrylkiewicz, I., Sliwinski, P., Hersh, C.P., Mancini, J.D., Lu, K., et al. (2012). Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. Hum. Mol. Genet. *21*, 1325–1335.

3. Castaldi, P.J., Guo, F., Qiao, D., Du, F., Naing, Z.Z.C., Li, Y., Pham, B., Mikkelsen, T.S., Cho, M., Silverman, E., et al. (2018). Identification of Functional Variants in the FAM13A COPD GWAS Locus by Massively Parallel Reporter Assays. American Journal of Respiratory and Critical Care Medicine *199*, 52–61.

4. Parker, M.M., Hao, Y., Guo, F., Pham, B., Chase, R., Platig, J., Cho, M., Hersh, C.P., Thannickal, V.J., Crapo, J.D., et al. (2019). Identification of an emphysema-associated genetic variant near TGFB2 with regulatory effects in lung fibroblasts. Elife *8*.

5. Boueiz, A., Pham, B., Chase, R., Lamb, A., Lee, S., Naing, Z.Z.C., Cho, M., Parker, M.M., Sakornsakolpat, P., Hersh, C.P., et al. (2019). Integrative Genomics Analysis Identifies ACVR1B as a Candidate Causal Gene of Emphysema Distribution. Am J Respir Cell Mol Biol *60*, 388–398.

6. Li, Y.I., van de Geijn, B., Raj, A., Knowles, D.A., Petti, A.A., Golan, D., Gilad, Y., and Pritchard, J.K. (2016). RNA splicing is a primary link between genetic variation and disease. Science *352*, 600–604.

7. Saferali, A., Yun, J.H., Parker, M.M., Sakornsakolpat, P., Chase, R.P., Lamb, A., Hobbs, B.D., Boezen, M.H., Dai, X., de Jong, K., et al. (2019). Analysis of genetically driven alternative splicing identifies FBXO38 as a novel COPD susceptibility gene. PLoS Genet *15*, e1008229.

8. Shrine, N., Guyatt, A.L., Erzurumluoglu, A.M., Jackson, V.E., Hobbs, B.D., Melbourne, C.A., Batini, C., Fawcett, K.A., Song, K., Sakornsakolpat, P., et al. (2019). New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nature Genetics *51*, 481–493.

9. The GTEx Consortium (2020). The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science *369*, 1318–1330.

10. Farh, K.K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S., Shoresh, N., Whitton, H., Ryan, R.J.H., Shishkin, A.A., et al. (2015). Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature *518*, 337–343.

11. Wu, E., Nance, T., and Montgomery, S.B. (2014). SplicePlot: a utility for visualizing splicing quantitative trait loci. Bioinformatics *30*, 1025–1026.

12. Picelli, S., Faridani, O.R., Björklund, Å.K., Winberg, G., Sagasser, S., and Sandberg, R.
(2014). Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc *9*, 171–181.

13. Byrne, A., Supple, M.A., Volden, R., Laidre, K.L., Shapiro, B., and Vollmers, C. (2019).
Depletion of Hemoglobin Transcripts and Long-Read Sequencing Improves the Transcriptome
Annotation of the Polar Bear (Ursus maritimus). Front Genet *10*, 403.

14. Volden, R., Palmer, T., Byrne, A., Cole, C., Schmitz, R.J., Green, R.E., and Vollmers, C.
(2018). Improving nanopore read accuracy with the R2C2 method enables the sequencing of
highly multiplexed full-length single-cell cDNA. Proceedings of the National Academy of
Sciences *115*, 9726–9731.

15. Cole, C., Byrne, A., Adams, M., Volden, R., and Vollmers, C. (2020). Complete
characterization of the human immune cell transcriptome using accurate full-length cDNA
sequencing. Genome Res. *30*, 589–601.

16. Volden, R., and Vollmers, C. (2020). Highly Multiplexed Single-Cell Full-Length cDNA
Sequencing of human immune cells with 10X Genomics and R2C2. bioRxiv *20*,
2020.01.10.902361.

17. Tardaguila, M., la Fuente, de, L., Marti, C., Pereira, C., Pardo-Palacios, F.J., Del Risco, H.,
Ferrell, M., Mellado, M., Macchietto, M., Verheggen, K., et al. (2018). SQANTI: extensive
characterization of long-read transcript sequences for quality control in full-length transcriptome
identification and quantification. Genome Res. *28*, 396–411.

18. UniProt Consortium (2019). UniProt: a worldwide hub of protein knowledge. Nucleic Acids
Research *47*, D506–D515.

18. Kumar, T., (2013). CFSSP: Chou and Fasman secondary structure prediction server. Wide
Spectrum *1*(9), 15–19.

20. Hiller, M., Huse, K., Szafranski, K., Jahn, N., Hampe, J., Schreiber, S., Backofen, R., and
Platzer, M. (2004). Widespread occurrence of alternative splicing at NAGNAG acceptors
contributes to proteome plasticity. Nature Genetics *36*, 1255–1257.

21. Bradley, R.K., Merkin, J., Lambert, N.J., and Burge, C.B. (2012). Alternative splicing of
RNA triplets is often regulated and accelerates proteome evolution. PLoS Biol. *10*, e1001229.

22. Brandenberger, R., Schmidt, A., Linton, J., Wang, D., Backus, C., Denda, S., Müller, U., and
Reichardt, L.F. (2001). Identification and characterization of a novel extracellular matrix protein
nephronectin that is associated with integrin alpha8beta1 in the embryonic kidney. J. Cell Biol.
154, 447–458.

23. Morimura, N., Tezuka, Y., Watanabe, N., Yasuda, M., Miyatani, S., Hozumi, N., and
Tezuka, K.-I. (2001). Molecular Cloning of POEM: A Novel Adhesion Molecule That Interacts
With α8β1 Integrin. Journal of Biological Chemistry *276*, 42172–42181.

24. Linton, J.M., Martin, G.R., and Reichardt, L.F. (2007). The ECM protein nephronectin
promotes kidney development via integrin alpha8beta1-mediated stimulation of Gdnf expression.
Development *134*, 2501–2509.

25. Kahai, S., Lee, S.-C., Seth, A., and Yang, B.B. (2010). Nephronectin promotes osteoblast
differentiation via the epidermal growth factor-like repeats. FEBS Lett. *584*, 233–238.

26. Steigedal, T.S., Toraskar, J., Redvers, R.P., Valla, M., Magnussen, S.N., Bofin, A.M.,
Opdahl, S., Lundgren, S., Eckhardt, B.L., Lamar, J.M., et al. (2018). Nephronectin is Correlated
with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs.
Neoplasia *20*, 387–400.

27. Lee, S., Honda, M., Yamamoto, S., Kumagai-Takei, N., Yoshitome, K., Nishimura, Y., Sada,
N., Kon, S., and Otsuki, T. (2019). Role of Nephronectin in Pathophysiology of Silicosis. Int J
Mol Sci *20*, 2581.

28. Toraskar, J., Magnussen, S.N., Hagen, L., Sharma, A., Hoang, L., Bjørkøy, G., Svineng, G.,
and Steigedal, T.S. (2019). A Novel Truncated Form of Nephronectin Is Present in Small
Extracellular Vesicles Isolated from 66cl4 Cells. J. Proteome Res. *18*, 1237–1247.

29. Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,
Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map
of the human proteome. Science *347*, 1260419–1260419.

30. Obeidat, M., Hao, K., Bossé, Y., Nickle, D.C., Nie, Y., Postma, D.S., Laviolette, M.,
Sandford, A.J., Daley, D.D., Hogg, J.C., et al. (2015). Molecular mechanisms underlying
variations in lung function: a systems genetics analysis. Lancet Respir Med *3*, 782–795.

31. Hancock, D., Eijgelsheim, M., Wilk, J.B., Gharib, S., Loehr, L., Marciante, K., Franceschini,
N., Durme, Y., Chen, T.-H., Barr, R.G., et al. (2010). Meta-analyses of genome-wide association
studies identify multiple loci associated with pulmonary function. Nature Genetics *42*, 45–52.

32. Parker, M.M., Foreman, M.G., Abel, H.J., Mathias, R.A., Hetmanski, J.B., Crapo, J.D.,
Silverman, E., Beaty, T.H., COPDGene Investigators (2014). Admixture mapping identifies a
quantitative trait locus associated with FEV1/FVC in the COPDGene Study. Genet. Epidemiol.
38, 652–659.

33. Soler Artigas, M., Wain, L.V., Miller, S., Kheirallah, A.K., Huffman, J.E., Ntalla, I., Shrine,
N., Obeidat, M., Trochet, H., McArdle, W.L., et al. (2015). Sixteen new lung function signals
identified through 1000 Genomes Project reference panel imputation. Nat Commun *6*, 8658.

34. Obeidat, M., Miller, S., Probert, K., Billington, C.K., Henry, A.P., Hodge, E., Nelson, C.P.,
Stewart, C.E., Swan, C., Wain, L.V., et al. (2013). GSTCD and INTS12 regulation and
expression in the human lung. PLoS ONE *8*, e74630.

35. Wain, L.V., Shrine, N., Artigas, M.S., Erzurumluoglu, A.M., Noyvert, B., Bossini-Castillo,
L., Obeidat, M., Henry, A.P., Portelli, M.A., Hall, R.J., et al. (2017). Genome-wide association

analyses for lung function and chronic obstructive pulmonary disease identify new loci and
potential druggable targets. Nature Genetics *49*, 416–425.

605